Pfizer releases 2025 financial report and 2026 strategic plan

K-LinePoet · 2026-03-11T20:16:03+00:00

Pfizer announced its 2025 performance, with Q4 revenue of $17.56 billion and total annual revenue of $62.6 billion. It is expected to generate $59.5 billion to $62.5 billion in revenue in 2026, with 20 clinical trials in development, focusing on obesity and oncology. Completed the $7 billion acquisition of Metsera to improve efficiency and reduce costs.

K-LinePoet

2026-03-11 20:16:03

Abstract generation in progress

Pfizer announced its Q4 and full-year 2025 results on February 3, 2026. Revenue for the fourth quarter was $17.56 billion, with non-COVID business up 9% year-over-year; full-year total revenue reached $62.6 billion, with non-COVID core business growing 6%. The company reaffirmed its 2026 revenue guidance of $59.5 billion to $62.5 billion, including approximately $5 billion in COVID-related product revenue and about $1.5 billion impact from patent expirations. Adjusted EPS guidance is $2.80 to $3.00.

Product Development Progress

In 2026, Pfizer plans to initiate about 20 key clinical trials, including 10 focused on obesity assets, such as the Phase 2b study of its long-acting GLP-1 receptor agonist PF-3944 (MET-097i), which has reached its primary endpoint. The oncology field has achieved several regulatory breakthroughs, such as FDA approval in November 2025 for Padcev combined with pembrolizumab for perioperative bladder cancer treatment, and significant efficacy shown in trials of Tukysa and Braftovi for breast and colorectal cancers.

Strategic Advancements

In November 2025, Pfizer completed its acquisition of Metsera, with a total deal valuation of approximately $7 billion, aimed at strengthening its obesity and metabolic disease pipeline. Operationally, the company improved efficiency through cost control, with adjusted gross margin decreasing to 24.2% in 2025, and sales and administrative expenses down 7% year-over-year.

The above information is compiled from public sources and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.